Perfluoroalkyl Substances, Sex Hormones, and Insulin-like Growth Factor-1 at 6-9 Years of Age: A Cross-Sectional Analysis within the C8 Health Project. by Lopez-Espinosa, Maria-Jose et al.
Lopez-Espinosa, MJ; Mondal, D; Armstrong, BG; Eskenazi, B; Fletcher,
T (2016) Perfluoroalkyl Substances, Sex Hormones, and Insulin-like
Growth Factor-1 at 6-9 Years of Age: A Cross-Sectional Analysis
within the C8 Health Project. Environmental health perspectives,
124 (8). pp. 1269-75. ISSN 0091-6765 DOI: https://doi.org/10.1289/ehp.1509869
Downloaded from: http://researchonline.lshtm.ac.uk/2537057/
DOI: 10.1289/ehp.1509869
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/about/pdm
Environmental Health Perspectives • volume 124 | number 8 | August 2016 1269
Research | Children’s HealthA Section 508–conformant HTML version of this article  is available at http://dx.doi.org/10.1289/ehp.1509869. 
Introduction
Perfluorohexane sulfonate (PFHxS), perfluoro­
octanoate (PFOA), perfluorooctane sulfonate 
(PFOS), and perfluorononanoic acid (PFNA) 
are members of the class of human­made 
perfluoroalkyl substances (PFAS) that are 
widely used in household and commercial 
products (Renner 2001; WHO 2013). Studies 
around the world have shown measurable 
levels of these four PFAS in the serum of the 
studied populations (Fromme et al. 2009; 
Halldorsson et al. 2012; Kato et al. 2011; 
Mondal et al. 2012) and, given their long half­
life in humans (Bartell et al. 2010), exposure to 
these compounds will persist for many years.
Even though humans are exposed to 
PFAS and they may disrupt the endocrine 
system (Jensen and Leffers 2008), little is 
known about their possible health effects. 
In some animal studies exposure to these 
contaminants has been linked with altera­
tions in levels of sex hormones (Lau et al. 
2007; Wan et al. 2011). However, few 
epidemiological data have been published on 
this topic despite the key roles played by sex 
hormones in developmental and reproduc­
tive functions during childhood and puberty 
(Norgil Damgaard et al. 2002; Schoeters 
et al. 2008). In a cross­sectional study of 
boys 8–18 years of age in the Mid­Ohio 
Valley, we reported a 6­month delay in 
the average age at which the boys entered 
puberty (using testosterone levels > 50 ng/dL 
as an indicator of having started puberty), 
comparing the highest and the lowest PFOS 
quartiles (Lopez­Espinosa et al. 2011). A 
study on Taiwanese boys 12–17 years of age 
(Tsai et al. 2015) reported an inverse associa­
tion between PFOS and follicle­stimulating 
hormone (FSH), but found no significant 
associations between PFAS and estrogen, 
testosterone, luteinizing hormone (LH), or 
sex hormone–binding globulin (SHBG). 
Information on adult male populations is also 
scarce and inconclusive. PFOS and PFNA 
were associated inversely with testosterone 
and estradiol (Joensen et al. 2013) and PFOA 
positively with LH and FSH (Vested et al. 
2013) in young Danish men with a mean 
age of around 20 years. In male American 
adults 30–66 years of age, positive associa­
tions between both PFOA and PFOS and 
LH were also reported (Raymer et al. 2012). 
Other studies, however, did not find such 
statistically significant associations (Olsen 
et al. 1998; Specht et al. 2012).
The relationship between PFAS and 
female reproductive hormones is not clear 
either. In girls 15 years of age from the 
ALSPAC (Avon Longitudinal Study of 
Parents and Children) cohort (UK), positive 
associations were found between prenatal 
PFHxS, PFOA, and PFOS exposure and 
testosterone (Maisonet et al. 2015). In 
contrast, inverse associations were found 
between PFOS and testosterone in Taiwanese 
girls 12–17 years of age (Tsai et al. 2015), 
but no significant associations were reported 
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Background: Exposure to some perfluoroalkyl substances (PFAS), such as perfluorohexane 
 sulfonate (PFHxS), perfluorooctanoate (PFOA), perfluorooctane sulfonate (PFOS), and perfluoro­
nonanoic acid (PFNA), may alter levels of sex hormones and insulin­like growth factor­1 (IGF­1) in 
animals. Human studies on this topic are scarce, and none have been conducted in young children.
oBjectives: We investigated the relationship between levels of PFAS and estradiol, total testos­
terone, and IGF­1 in 2,292 children (6–9 years of age) from the C8 Health Project who lived near a 
chemical plant in the Mid­Ohio Valley (USA) with local contamination from PFOA.
Methods: Serum samples were collected in 2005–2006 and analyzed for PFAS, sex hormones, 
and IGF­1. Results from regression models were expressed as the adjusted percentage difference 
(95% CI) per sex­specific interquartile range (IQR) increment of each PFAS serum concentration. 
Analyses by PFAS quartiles were also conducted.
results: Median concentrations of PFHxS, PFOA, PFOS, and PFNA were 8, 35, 22, and 
1.7 ng/mL in boys and 7, 30, 21, and 1.7 ng/mL in girls. In boys, PFOA concentrations were 
significantly associated with testosterone levels (–4.9%; 95% CI: –8.7, –0.8%); PFOS with 
estradiol (–4.0%; 95% CI: –7.7, –0.1%), testosterone (–5.8%; 95% CI: –9.4, –2.0%), and 
IGF­1 (–5.9%; 95% CI: –8.3, –3.3%); and PFNA with IGF­1 (–3.5%; 95% CI: –6.0, –1.0%). 
In girls, significant associations were found between PFOS and testosterone (–6.6%; 95% CI: 
–10.1, –2.8%) and IGF­1 (–5.6%; –8.2, –2.9%); and PFNA and IGF­1 (–3.8%; 95% CI: 
–6.4, –1.2%). In both sexes, the magnitudes of the associations decreased monotonically across 
quartiles for both testosterone and IGF­1 in relation to PFOS, and for IGF­1 and PFNA in girls.
conclusions: To our knowledge, this is the first study suggesting that PFAS are associated with 
lower levels of IGF­1 and sex hormones in young children.
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between prenatal PFOA or PFOS exposure 
and estradiol or testosterone in 20­year­old 
Danish women (Kristensen et al. 2013). 
In addition, an inverse association between 
PFOS and estradiol levels was reported 
among perimenopausal and menopausal 
women in the Mid­Ohio Valley (Knox et al. 
2011). However, an explanation for the 
pattern found by Knox et al. (2011) may be 
reverse causality through menopause, leading 
to lower excretion rates (via menstrual blood 
loss) and thus higher PFAS concentrations 
in serum (Konkel 2014; Taylor et al. 2014). 
Other hormones and proteins involved in 
sexual maturation have also been studied 
in the previous studies. SHBG levels were 
inversely associated with PFOA in girls 
12–17 years of age from the Taiwanese cohort 
(Tsai et al. 2015), but such significant asso­
ciation was not observed in 15­year­old girls 
from the UK cohort (Maisonet et al. 2015). 
Also, no statistically significant associations 
were found between PFAS and LH or FSH in 
adolescent girls (Kristensen et al. 2013; Tsai 
et al. 2015).
In addition to sex hormones, insulin­like 
growth factor­1 (IGF­1) also plays impor­
tant roles in growth and sexual maturation. 
Dynamic interactions taking place among 
growth hormone (GH), IGF­1, and sex 
hormones increase muscle mass, affect the 
mineralization of the skeleton, and control 
growth and metabolic changes during the 
prepubertal and pubertal periods (Garnett 
et al. 2004; Le Roith and Butler 1999; Mauras 
2001). IGF­1 stimulates testosterone synthesis 
and maintains normal fertility in males 
(Wan et al. 2011). It is also involved in the 
development and maturation of the pubertal 
mammary gland in females (Kleinberg and 
Ruan 2008), and has been shown to predict 
the age of menarche (Thankamony et al. 
2012). In addition, IGF­1 levels in childhood 
and adolescence are predictive of IGF­1 levels 
in adulthood (Sandhu et al. 2006), and lower 
levels of IGF­1 in adults have been associ­
ated with diabetes, cardiovascular diseases, and 
an increased risk of mortality (Burgers et al. 
2011; Ceda et al. 2005; Vaessen et al. 2001). 
Well­known factors influencing IGF­1 levels 
are diet and lifestyle (Baibas et al. 2003; Berg 
and Bang 2004; Savage 2013), but exposure 
to endocrine­disrupting chemicals may also 
alter the normal synthesis and/or secretion 
of IGF­1 (Zumbado et al. 2010). However, 
to our knowledge, no data on the association 
between IGF­1 and PFAS in humans have 
been published to date.
In this study we aimed to assess the asso­
ciation between serum concentrations of four 
PFAS (PFHxS, PFOA, PFOS, and PFNA) 
and total testosterone, estradiol, and IGF­1 in 
6­ to 9­year­old children from the Mid­Ohio 
Valley, USA.
Material and Methods
Study Participants
Data on 69,030 people were collected in 
the “C8 Health Project” between August 
2005 and July 2006. The details of the 
study, participants, enrollment criteria, and 
consent procedures are described elsewhere 
(Frisbee et al. 2009). PFOA had been used 
in the manufacture of fluoropolymers at a 
chemical plant in Parkersburg, West Virginia, 
since 1951 and led to contamination of local 
drinking water with PFOA. Individuals 
were eligible to participate in the C8 Health 
Project if they had consumed water for at 
least 1 year between 1950 and 2004 from the 
six contaminated water districts or private 
wells in the proximity of the chemical plant.
For this study, we focused on the subset of 
children 6–9 years of age at enrollment. We 
set a minimum of 6 years because the propor­
tion of children with hormone levels below the 
detection limit (LOD) rose sharply below age 
6 years, and a maximum of 9 years was estab­
lished to largely avoid including children who 
had started their pubertal development. Four 
boys had entered puberty using the criterion 
of testosterone levels > 50 ng/dL as a marker 
(Lopez­Espinosa et al. 2011), and 13 girls 
reported menarche by the time of the survey. 
These 17 children (0.7%) were excluded. Of 
the remaining children, 96% had measures 
of PFAS, hormones, and/or IGF­1, resulting 
in a final sample size of 2,292. Parents or 
guardians provided written informed consent 
on behalf of the children participating in the 
present study. The London School of Hygiene 
and Tropical Medicine Ethics Committee 
approved this study.
Determination of PFAS
Laboratory analyses of serum PFAS were 
conducted by a commercial laboratory 
(Exygen Research). Samples collected at 
survey were analyzed for 10 PFAS including 
PFHxS, PFOA, PFOS, and PFNA. The 
analytical methods and quality control 
procedures employed by the laboratory have 
been described elsewhere (Flaherty et al. 
2005; Frisbee et al. 2009). Briefly, the tech­
nique used solid­phase extraction followed 
by reverse­phase high­performance liquid 
 chromatography/mass spectrometry. Over 
a range of 0.5–40 ng/mL, the coefficient of 
variation (CV) for PFOA was generally < 10% 
for multiple samples measured in different 
batches. CVs for PFHxS, PFOS, and PFNA 
were similar to those for PFOA. The LOD 
was 0.5 ng/mL for all of them. A quality assur­
ance program was carried out by analysis of 
duplicate samples at AXYS Analytical Service 
Ltd. Details on the interlaboratory reliability 
have been extensively reported by Frisbee 
et al. (2009).
Determination of Sex Hormones 
and IGF-1
Clinical laboratory tests were performed at 
an accredited clinical diagnostic laboratory 
(LabCorp). Estradiol and total testosterone 
levels were measured in serum samples using 
an electrochemiluminescence immunoassay 
(Roche Diagnostics) with LODs of 7 pg/mL 
and 10 ng/dL, respectively. Free testosterone 
was measured by a radioimmunoassay in 
serum (Coat­a­Count; Siemens Healthcare 
Diagnostics) with an LOD of 0.2 pg/mL. 
IGF­1 was measured in serum by an immu­
nochemiluminometric assay (Siemens 
Healthcare Diagnostics) with an LOD of 
25 ng/mL. Volumes used for analyses were: 
35, 50, 50, and 20 μL for estradiol, total 
testosterone, free testosterone, and IGF­1, 
respectively. A total of 33.4% of the blood 
samples were drawn before 1200 hours, 
43.6% between 1200 and 1600 hours, and 
23.0% between 1700 and 1900 hours.
Covariates
Covariates selected a priori for the analyses 
included sex, race/ethnicity (non­Hispanic 
white and others), age (years), height (inches), 
weight (pounds), body mass index (BMI; 
kilograms per meter squared) transformed 
into a z­score based on the 2000 U.S. Centers 
for Disease Control and Prevention growth 
charts of height/weight/BMI­for­age (CDC 
2010), household annual family income 
(classified in the original questionnaire as 
≤ $20,000; $20,000–70,000; > $70,000; 
and not known), and the month and hour of 
sample collection.
Statistical Analyses
We present descriptive analyses for the three 
sex hormones and IGF­1, but free testos­
terone was excluded from the multivariate 
analyses due to the low proportion of samples 
above the LOD. Outcomes showed a non­
normal distribution and were natural log 
transformed before inclusion in the models.
PFAS observations below the LOD 
(< 0.5% for all the PFAS) were replaced by 
the LOD divided by 2 for descriptive and 
statistical analyses. PFAS did not show a 
normal distribution either and were natural 
log transformed as well as categorized in 
quartiles for the statistical analyses. We used 
simple Pearson’s correlations to describe 
pairwise relationships between ln(PFAS).
We used interval regression for censored 
data to assess the relation between outcomes 
and ln(PFAS) or PFAS in quartiles. These 
models were constructed to provide maximum 
likelihood estimations of the coefficients 
in the presence of LODs in the dependent 
variable (Lubin et al. 2004). All models were 
adjusted for child’s age and sampling month 
(because of a trend in serum PFAS during the 
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collection year as well as seasonal variations in 
levels of hormones and IGF­1). Total testos­
terone models were additionally adjusted for 
time of day of blood sampling due to diurnal 
variations in their levels. Race did not meet our 
operational definition of confounder because 
there was < 10% change in the PFAS coef­
ficients when including or excluding it from 
the final regression models. Analyses were sex­
stratified, but we also investigated differences 
by sex including the interaction of this variable 
with the contaminants in the joint models (i.e., 
models including both girls and boys).
For PFAS as continuous variables, we 
expressed results as percentage difference [with 
95% confidence interval (CI)] in the outcomes 
associated with a sex­specific interquartile 
range (IQR) increment in PFAS concentra­
tions, and the percentage was calculated as the 
complement of the exponentiated regression 
coefficient [100×(exp(β × IQR) – 1)]. For 
PFAS in quartiles, we expressed results as the 
percentage difference (95% CI) in outcome 
across quartiles of exposure (with the lowest as 
the reference). Tests for trend were conducted 
across quartiles using a variable with the 
median concentration of PFAS in each quartile 
added to models as a numerical regressor. 
Finally, we also fitted multi­pollutant models 
including all four ln(PFAS) in the same model.
We used the multivariate imputation 
procedure by chained equations (Horton and 
Kleinman 2007; van Buuren and Groothuis­
Oudshoorn 2011) to impute missing values 
according to available information. Variables 
included in the procedure were eligible for 
inclusion based on prediction ability (correla­
tion ≥ 0.05), their relation to the nonresponse 
(correlation ≥ 0.05), and the existence of 
at least 20% with known values within the 
subgroup of incomplete cases (van Buuren 
and Groothuis­Oudshoorn 2011), including 
the outcome and exposure variables, covari­
ates, and other predictors not included in 
the main analyses, without interactions (see 
Table S1). We imputed 50 data sets (20 
cycles for each) and assessed convergence by 
plotting parameters (mean and SD in each 
imputed data set) against iteration number. In 
addition, we checked imputations of missing 
values graphically, and compared them with 
observed data.
We performed sensitivity analyses with 
these imputed data. First, we considered 
the imputed variable household income as a 
possible confounder in our analyses although 
it did not meet our operational definition of 
confounder. Missing values for this variable 
(n = 344, 15%) were imputed according to 
available data for maternal education, current 
employment, and mother’s and child’s race 
(see Table S1). We also reran analyses after 
excluding individuals with missing house­
hold income data, and found no noteworthy 
changes in the results (data not shown). 
Second, the main analyses were not adjusted 
for height or BMI because these variables may 
be affected by outcomes. However, people 
who are larger at a given age might have higher 
IGF­1 levels, and there is some concern that 
growth (and increased body volume) resulting 
from higher IGF­1 levels might cause PFAS 
concentrations to decrease. The same process 
could occur with sex hormones, because they 
also influence growth. Therefore, to assess the 
possibility of reverse causality or confounding 
by growth, we also carried out sensitivity 
analyses by additionally adjusting for the 
imputed height or BMI variable (in quartiles 
according to sex). Missing values for BMI 
(n = 366) and height (n = 348) were imputed 
according to available data for child sex, 
frequency of exercise per week of the children, 
and anthropometric measures of the children 
and mothers (see Table S1). No remarkable 
changes in results were found when restricting 
analyses to individuals with available data for 
these two variables (data not shown).
In all the analyses, we excluded highly 
influential observations detected by exami­
nation of graphical representation of dfbetas 
(range, 0–3 observations excluded). We used 
the statistical software package STATA for all 
statistical analyses, and specifically the “intreg” 
command for interval (censored) regression 
(STATA Statistical Software, Release 12), and 
the statistical software R.3.1.1 (R Core Team 
2014) for multiple imputation (mice package 
(van Buuren and Groothuis­Oudshoorn 
2011). Where associations are referred to as 
statistically significant, this implies a p < 0.05.
Results
Table 1 shows the characteristics of the study 
participants (n = 2,292) and Table 2 the 
summary figures for sex steroid hormones, 
IGF­1, and PFAS. A total of 96% of the 
children were white, the annual household 
family income was < $20,000 in 34% of 
them, and 51% were boys (Table 1). Levels of 
sex hormones and IGF­1 were slightly higher 
in girls than in boys. The proportion of obser­
vations in boys and girls above the LODs were 
73% and 80% for estradiol, 69% and 75% 
for total testosterone, 19% and 28% for free 
testosterone, and 99.9% and 100% for IGF­1 
(Table 2). Median concentrations of PFHxS, 
PFOA, PFOS, and PFNA in boys were 8, 35, 
22, 1.7 ng/mL, and in girls they were 7, 30, 
21, 1.7 ng/mL, respectively (Table 2). In boys 
and girls, correlations between the four PFAS 
were low (range of r = –0.08 and 0.33), except 
for PFOS versus PFHxS (r = 0.56 and 0.61 in 
boys and girls) (see Table S2).
As soc i a t ions  be tween  PFAS and 
outcomes in children are shown in Table 3 
and Figures 1–2 (see also Tables S3–S6). 
Any difference in effect by sex was assessed 
through interaction terms between sex and 
the contaminants in joint models (including 
boys and girls). The interaction with sex was 
not statistically significant except for PFOS 
and estradiol (p = 0.048) (Table 3). In the 
stratified models for boys, significant inverse 
associations were observed for PFOA and total 
testosterone (–4.9%; 95% CI: –8.7, –0.8%), 
PFOS and estradiol (–4.0%; 95% CI: 
–7.7, –0.1%), PFOS and total testosterone 
(–5.8%; 95% CI: –9.4, –2.0%), PFOS and 
Table 1. C8 Health Study Participants (n = 2,292), Mid-Ohio Valley (USA), 2005–2006.
Variable Boys (n = 1,169) Girls (n = 1,123)
Race/ethnicity (white) 1,120 (95.8) 1,075 (95.7)
Household income (< $20,000) 334 (33.9) 336 (34.9)
Age (years) 8.3 (7.3, 9.3) 8.4 (7.3, 9.3)
Body mass index (kg/m2) 17.9 (15.6, 20.8) 17.4 (15.3, 20.5)
Height (inches) 51.0 (48.0, 54.0) 50.0 (48.0, 53.5)
Values are n (%) or median (interquartile range). The n (%) of missing values in boys and girls was as follows: household 
annual family income: 184 (16%) and 160 (14%); body mass index: 179 (15%), and 187 (17%); and height: 168 (14%) and 180 
(16%). Missing values were not considered for descriptive analyses.
Table 2. Levels of sex hormones, IGF-1 and PFAS in children 6–9 years years of age (n = 2,292), Mid-Ohio 
Valley (USA), 2005–2006.
Hormone, IGF-1, and PFAS LOD
Boys (n = 1,169) Girls (n = 1,123)
n > LOD (%) Median (IQR) n > LOD (%) Median (IQR)
Estradiol (pg/mL) 7 846 (72.6) 10 (< LOD, 15) 896 (80.0) 12 (LOD, 17)
Total testosterone (ng/dL) 10 809 (69.2) 13 (< LOD, 18) 840 (74.8) 15 (< LOD, 21)
Free testosterone (pg/mL) 0.2 216 (19.0) < LOD (< LOD, 15) 313 (28.0) < LOD (< LOD, 17)
IGF-1 (ng/mL) 25 1,159 (99.9) 147 (116, 187) 1,112 (100) 185 (142, 234)
PFHxS (ng/mL) 0.5 1,166 (99.7) 8.1 (4.2, 17.1) 1,120 (99.7) 7.0 (3.8, 13.8)
PFOA (ng/mL) 0.5 1,169 (100) 34.8 (15.3, 82.2) 1,123 (100) 30.1 (13.5, 74.0)
PFOS (ng/mL) 0.5 1,166 (99.7) 22.4 (16.5, 32.0) 1,123 (100) 20.9 (15.3, 29.4)
PFNA (ng/mL) 0.5 1,162 (99.4) 1.7 (1.3, 2.3) 1,119 (99.6) 1.7 (1.3, 2.4)
Abbreviations: IGF-1, insulin-like growth factor-1; IQR, interquartile range; LOD, detection limit; PFAS, perfluoroalkyl 
substances; PFHxS, perfluorohexane sulfonate; PFNA, perfluorononanoic acid; PFOA, perfluorooctanoate; PFOS, perflu-
orooctane sulfonate. The n (%) of missing values in boys and girls was as follows: estradiol: 3 (0.26%) and 3 (0.27%); total 
testosterone: 0 (0%) and 0 (0%); free testosterone: 5 (0.43%) and 5 (0.45%); and IGF-1: 9 (0.77%) and 11 (0.98%). Missing 
values were not considered for descriptive analyses.
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IGF­1 (–5.9%; 95% CI: –8.3, –3.3%), 
and PFNA and IGF­1 (–3.5%; 95% CI: 
–6.0, –1.0%) (Table 3 and Figure 1). The 
magnitudes of the estimates were similar after 
adjustment for other PFAS or after including 
height or BMI in the models (see Table S3). 
Associations between each PFAS (in quartiles) 
and outcomes in boys are shown in Figure 1 
(see also Table S5) where the lowest quartile is 
the reference exposure category. The decrease 
across PFAS quartiles was most clearly mono­
tonic in the case of PFOS and both total 
testosterone (p­trend across quartiles = 0.002) 
and IGF­1 (p­trend < 0.001) and less clearly 
for PFNA and IGF­1 (p­trend = 0.031) 
(see Table S5).
In the stratified models for girls (Table 3 
and Figure 2), significant inverse associations 
were found for PFOS and total testosterone 
(–6.6%; 95% CI: –10.1, –2.8%), PFOS 
and IGF­1 (–5.6%; 95% CI: –8.2, –2.9%), 
and PFNA and IGF­1 (–3.8%; 95% CI: 
–6.4, –1.2%). For PFOA, an association 
with IGF­1 was also found (–3.6%; 95% CI: 
–6.6, –0.5%) (Table 3), but this appeared to 
be an artifact of the raised mean IGF­1 in the 
second quartile (Figure 2; see also Table S6). 
Associations were similar after adjustment 
for other PFAS and results were also gener­
ally consistent when height or BMI was 
included (see Table S4). Across PFAS quartiles 
(Figure 2; see also Table S6), we found a more 
clearly monotonic decrease in total testos­
terone or IGF­1 in relation to concentrations 
of PFOS (p­trend across quartiles = 0.002 and 
< 0.001, respectively), and IGF­1 and PFNA 
(p­trend = 0.021).
Discussion
We found serum PFAS concentrations to be 
associated with lower levels of sex hormones 
and IGF­1 in children 6–9 years of age. 
Across sexes, PFOS exposure was found to 
be more clearly related to the outcomes in 
young children. Concerning outcomes, IGF­1 
was the most consistently associated with 
PFAS exposures.
In boys 6–9 years of age, serum PFOS 
concentrations were associated with lower 
estradiol, total testosterone, and IGF­1 levels. 
PFOA was also inversely associated with 
total testosterone, and PFNA with IGF­1. 
A statistically significant delay in the age at 
which boys started pubertal development 
(defined by testosterone levels > 50 ng/dL) 
was found for PFOS but not PFOA in the 
8­ to 18­year group of the same population 
(Lopez­Espinosa et al. 2011), supporting the 
current findings. Although the age of hormone 
measurement is not the same, and comparisons 
ought to be made with caution, our results 
in young children are also consistent with 
inverse associations between PFOS (median, 
Table 3. Difference in levels of sex hormones and IGF-1 in relation to PFAS concentrations in children 
6–9 years of age (n = 2,292), Mid-Ohio Valley (USA), 2005–2006.
PFAS
Stratified, boys (n = 1,169) 
[% difference (95% CI)]a
Stratified, girls (n = 1,123) 
[% difference (95% CI)]a
Joint 
p-interb
Association with ln(estradiol)c
PFHxS –1.3 (–5.5, 3.1) 2.1 (–2.2, 6.5) 0.165
PFOA 4.3 (–0.4, 9.1) 4.2 (–0.7, 9.4) 0.924
PFOS –4.0 (–7.7, –0.1) –0.3 (–4.6, 4.2) 0.048
PFNA –2.5 (–6.2, 1.4) –2.4 (–6.3, 1.7) 0.622
Association with ln(total testosterone)d
PFHxS –2.7 (–6.4, 1.2) 0.2 (–3.5, 4.0) 0.252
PFOA –4.9 (–8.7, –0.8) –2.5 (–6.7, 1.8) 0.425
PFOS –5.8 (–9.4, –2.0) –6.6 (–10.1, –2.8) 0.531
PFNA –2.1 (–5.5, 1.3) –1.9 (–5.5, 1.9) 0.700
Association with ln(IGF-1)c
PFHxS –2.5 (–5.2, 0.3) –2.1 (–4.8, 0.7) 0.829
PFOA –0.4 (–3.4, 2.7) –3.6 (–6.6, –0.5) 0.057
PFOS –5.9 (–8.3, –3.3) –5.6 (–8.2, –2.9) 0.761
PFNA –3.5 (–6.0, –1.0) –3.8 (–6.4, –1.2) 0.829
Abbreviations: CI, confidence interval; IGF-1, insulin-like growth factor-1; PFAS, perfluoroalkyl substances; PFHxS, 
perfluorohexane sulfonate; PFNA, perfluorononanoic acid; PFOA, perfluorooctanoate; PFOS, perfluorooctane sulfonate.
aPercent difference in outcome in relation to 75th vs. 25th percentile of ln(PFAS), derived from multiple linear regression 
model of outcome on ln(PFAS). The interquartile ranges in boys were 1.40, 1.68, 0.66, and 0.57 for ln(PFHxS), ln(PFOA), 
ln(PFOS), and ln(PFNA), respectively. Corresponding data in girls were 1.29, 1.70, 0.65, and 0.61. bp-Value from the inter-
action term between PFAS and sex in joint models.cModels adjusted for age and month of sampling. dModel adjusted for 
age, month, and time of sampling.
Figure 1. Difference in levels of sex hormones and IGF-1 in relation to PFAS (continuous or quartiles) in boys 6–9 years of age (n = 1,169), Mid-Ohio Valley (USA), 
2005–2006. 
Abbreviations: IGF-1, insulin-like growth factor-1; PFAS, perfluoroalkyl substances; PFHxS, perfluorohexane sulfonate; PFNA, perfluorononanoic acid; PFOA, perfluorooctanoate; 
PFOS, perfluorooctane sulfonate; Q, quartile; Ref, reference. Models were adjusted for age and month of sampling. In addition, testosterone models were adjusted for time of sample 
 collection. Estimates and 95% confidence intervals are presented. p-Trend was < 0.05 for PFOA or PFOS and total testosterone, and PFOS or PFNA and IGF-1.
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7.79 ng/mL) and testosterone in Danish men 
with a mean age of 19.6 years (Joensen et al. 
2013). In contrast, no significant associations 
between PFOS and these hormones were 
found in a study of Taiwanese adolescent boys 
12–17 years of age (Tsai et al. 2015) or in 
adult men from different European countries 
(median range, 7.6–44.7 ng/mL) (Specht et al. 
2012; Vested et al. 2013). Concerning PFOA, 
neither an epidemiological study in adolescent 
boys (Tsai et al. 2015) nor those conducted 
in adult men with background or with high 
occupational PFOA exposure (median range, 
3.02 ng/mL–5.71 μg/mL) found statisti­
cally significant associations with estradiol or 
testosterone (Costa et al. 2009; Joensen et al. 
2013; Raymer et al. 2012). PFHxS and PFNA 
have been more rarely studied (Joensen et al. 
2013; Tsai et al. 2015), and only one study 
found an inverse association between PFNA 
(median, 1.07 ng/mL) and estradiol in young 
men (Joensen et al. 2013). PFOS and PFNA 
levels in young boys were also associated with 
IGF­1 in the present study, but, to our knowl­
edge, there are no previous epidemiological 
studies with which to compare our results, 
and this observation should be investigated in 
other populations.
In girls 6–9 years of age, we found PFOS 
to be associated with lower total testosterone 
and IGF­1 levels. PFNA was also inversely 
associated with IGF­1. There was no signifi­
cant association between any of the four 
PFAS that were studied and estradiol levels. 
In previous studies, testosterone was found 
to be inversely associated with PFOS among 
Taiwanese girls 12–17 years of age (Tsai et al. 
2015). In contrast, prenatal concentrations of 
PFHxS, PFOA and PFOS (medians, 1.6, 3.6, 
and 19.2 ng/mL, respectively) were positively 
associated with testosterone in girls 15 years 
of age from the ALSPAC cohort (UK) 
(Maisonet et al. 2015). Neither estradiol nor 
testosterone measured in 20­year­old Danish 
women (Kristensen et al. 2013) was statis­
tically significantly associated with in utero 
PFOA or PFOS concentrations (medians, 
3.6 and 21.1 ng/mL, respectively). To our 
knowledge, the association between IGF­1 
and PFOS or PFNA observed in the present 
study has not been reported previously in girls 
either and needs to be further investigated.
Levels of sex hormones and IGF­1 during 
the prepubertal period or around onset of 
puberty are associated with age at menarche 
(Apter and Vihko 1985; Thankamony et al. 
2012). Therefore, our findings of a relatively 
modest decrease in levels of testosterone and 
IGF­1 in girls who had not reported their 
first period yet might be of concern, because 
later menarche attainment was associated 
with exposure to these contaminants in two 
previous investigations. A 5.3­month delay 
in the age of menarche between the lowest 
and highest tertile of prenatal PFOA exposure 
was reported in young Danish women 
(Kristensen et al. 2013). We also found a 4.3­ 
and 4.6­month delay in the age of menarche 
when comparing the 1st and 4th quartiles of 
PFOA and PFOS concentrations in the 8­ to 
18­year­old girls of the C8 Health Project 
(Lopez­Espinosa et al. 2011). Our study was 
cross­sectional, so physiological changes, 
including menstrual blood loss, could have 
affected PFAS excretion and thus serum 
concentrations. In fact, a pharmacokinetic 
model (Wu et al. 2015) has recently indi­
cated that growth dilution and excretion of 
the contaminants through menstruation may 
cause lower PFAS concentrations in serum. 
This might explain, in part, the association 
between higher PFAS concentrations and 
older age of menarche in our previous study 
(Lopez­Espinosa et al. 2011). Finally, a nested 
case–control study conducted in the ALSPAC 
cohort did not find a significant association 
between cord blood PFAS concentrations and 
the age of menarche (Christensen et al. 2011).
The possible biological mechanisms 
underlying the potential effects of PFAS on 
decreasing levels of sex hormones and IGF­1 
are still not well understood, but several 
modes of action may be involved. Thus, 
some animal evidence exists on their possible 
effects on androgen synthesis. Concerning 
PFOA­exposed male rodents, a decrease in 
testosterone production was found to be 
due to the reduction in the conversion of 
17α­hydroxyprogesterone to androstenedione 
(Cook et al. 1992) and to the inhibition of 
3β­ and 17β­hydroxysteroid dehydrogenase 
activities in Leydig cells (Zhao et al. 2010). 
For PFOS, the decrease in testosterone levels 
was attributed to a reduction in the expres­
sion levels of testicular receptors for FSH, 
LH, GH, IGF­1, and inhibin subunits as well 
as to the impairment of testicular steroido­
genesis in PFOS­exposed male mice (Wan 
et al. 2011) and to the impairment of fetal 
Leydig cells in male fetus of prenatally PFOS 
exposed rats (Zhao et al. 2014). PFAS could 
Figure 2. Difference in levels of sex hormones and IGF-1 in relation to PFAS (continuous or quartiles) in girls 6–9 years of age (n = 1,123), Mid-Ohio Valley (USA), 
2005–2006. 
Abbreviations: IGF-1, insulin-like growth factor-1; PFAS, perfluoroalkyl substances; PFHxS, perfluorohexane sulfonate; PFNA, perfluorononanoic acid; PFOA, perfluorooctanoate; 
PFOS, perfluorooctane sulfonate; Q, quartile; Ref, reference. Models were adjusted for age and month of sampling. In addition, testosterone models were adjusted for time of sample 
 collection. Estimates and 95% confidence intervals are presented. p-Trend was < 0.05 for PFOS and total testosterone or IGF-1, and PFNA and IGF-1.
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also interfere with the androgen or estrogen 
pathway by disturbing the expression of genes 
associated with the metabolism of steroid 
hormones, as reported in liver tissue from 
PFOA­exposed mouse fetuses (Rosen et al. 
2007) or decreasing the expression of genes 
related to the hypothalamic–pituitary–thyroid 
(HPT) axis, the growth hormone–insulin­like 
growth factor axis (GH–IGF), and the steroid 
hormone axis, as reported in salmon embryos 
and larvae exposed to PFOA and PFOS 
(Spachmo and Arukwe 2012).
The main strengths of the present study 
are the large sample size (over 2,000 partici­
pants) and the several individual potential 
confounders considered in our models. It is 
believed that these participants are representa­
tive, given the high participation rates in the 
C8 Health Project (77% in the 5–10 year 
age group) (Frisbee et al. 2009) among those 
children who drank contaminated water in the 
Mid­Ohio Valley, and this diminishes concern 
about potential selection biases. Notably, the 
strongest significant associations were found for 
PFOS, whose concentrations in the Mid­Ohio 
Valley participants were similar to the general 
U.S. population, assessed in the 2005–2006 
National Health and Nutrition Examination 
Survey (NHANES) (Kato et al. 2011). 
Although NHANES information in children 
6–9 years of age was not available, median 
concentrations of PFOS were 15 ng/mL in 
NHANES children 12–19 years of age versus 
20 ng/mL in 2005–2006 C8 Health Project 
children 11–17 years of age (Lopez­Espinosa 
et al. 2012). However, patterns of human 
exposure to PFOS are changing worldwide as 
a consequence of changes in regulatory policies 
and PFOS exposure levels have decreased in the 
United States (Kato et al. 2011). Therefore, the 
levels reported in the present study may not be 
representative of current serum levels.
The 6–9 years age group was selected to 
investigate possible alterations in biomarkers 
involved in sexual maturation and growth 
due to PFAS exposure before or around the 
onset of puberty (i.e. entry to Tanner stage 2). 
We excluded boys who had started puberty 
(considered by the authors as testosterone 
levels > 50 ng/dL) and girls with menarche, 
but we were unable to differentiate children 
in different pubertal Tanner stages. We 
presume that some of our children might be 
in Tanner stage 2 or higher since according 
to a study (n = 2,070; collection period, 
2005–2010), 26.1% (95% CI: 19.5, 33.6) 
and 8.1% (95% CI: 4.4, 13.4) of American 
non­Hispanic white boys had experienced 
the onset of genital and pubic hair develop­
ment, respectively, at the age of 9 years 
(Herman­Giddens et al. 2012). In American 
non­Hispanic white girls (n = 420; collection 
period, 2004–2011), the median age of onset 
of breast development was 9.7 years (Biro 
et al. 2013). Our cross­sectional design has 
different limitations. First, we cannot rule 
out the possibility that growth (and associ­
ated IGF­1 increases) may actually cause a 
reduction in these PFAS by diluting them in 
a growing body or by affecting excretion rates. 
We consider this unlikely, because adding 
height or BMI (as markers of growth) to the 
models made no difference to the associa­
tions. Second, our findings suggest a possible 
alteration of sex hormones and IGF­1 due to 
PFAS exposure at 6–9 years of age, which is 
a period of high vulnerability to the possible 
effects of exposure to chemicals with endo­
crine properties, such as the PFAS. But apart 
from this period of life, there are also others, 
such as the fetal stage, in which the develop­
ment of the hypthalamic–pituitary–gonadal 
(HPG), HPT, or GH­IGF axes, ovaries, and 
testicles could have been negatively affected at 
any level. Third, we had a single measure of the 
levels of these biomarkers, which are constantly 
changing in this period. In fact, their levels 
gradually increase from mid­childhood, rise 
sharply in puberty and decline steadily with 
age for IGF­1 (Pollak 2000), and continue to 
rise after puberty for sex hormones (Cole et al. 
2015; Garnett et al. 2004). Therefore, further 
longitudinal studies need to be conducted 
to examine several periods of vulnerability. 
Another weakness of the present study is the 
lack of other markers of growth or pubertal 
development such as LH, FSH, or GH, which 
would have yielded more comprehensive 
information concerning the functioning of 
the HPG and GH­IGF axes. Finally, serum 
testosterone levels exhibit variable diurnal 
cyclicity (Ankarberg and Norjavaara 1999; 
Ankarberg­Lindgren and Norjavaara 2004), 
but the adjustment of models by the timing of 
sample collection enabled us to limit potential 
confounding from diurnal fluctuations.
Conclusions
Our findings show PFOS and PFNA concen­
trations to be associated with lower levels 
of IGF­1 in boys and girls 6–9 years of age. 
Our results also suggest an inverse associa­
tion between PFAS and sex hormones with a 
decrease in testosterone in both boys and girls 
for PFOS and for PFOA in boys. PFOS was 
also inversely associated with estradiol only in 
boys. PFOS appears to be the most active of 
the four compounds studied in affecting sex 
hormones and IGF­1 in young children.
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